HDAC6 and plasma cell myeloma: The effect of HDAC6 inhibitors on each proteasome catalytic activity in multiple myeloma cells was measured using peptide-based fluorescent reporters that are preferentially cleaved by the distinct catalytic sites (Fig. 1G; Supplementary Table S4).